piperacillin has been researched along with avibactam in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beaudoin, ME; Cavalcanti, NC; Derendorf, H; Grunwitz, C; Kircher, P; Nichols, WW; Pieper, S; Schuck, VJ; Sy, SK; Tabosa, MA; Zhuang, L | 1 |
Barkan, D; Bifani, P; Meir, M | 1 |
Abodakpi, H; Byerly, C; Chang, KT; Tam, VH; Zhou, J | 1 |
Barnes, MD; Becka, SA; LiPuma, JJ; Papp-Wallace, KM; Wilson, BM; Zeiser, ET | 1 |
4 other study(ies) available for piperacillin and avibactam
Article | Year |
---|---|
Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Drug Synergism; Kinetics; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tandem Mass Spectrometry; Thienamycins | 2017 |
The addition of avibactam renders piperacillin an effective treatment for
Topics: Animals; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Disease Models, Animal; Drug Combinations; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Moths; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Piperacillin | 2018 |
A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Dose-Response Relationship, Drug; Drug Synergism; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2019 |
"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Burkholderia gladioli; Burkholderia Infections; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Substitution; Humans; Kinetics; Microbial Sensitivity Tests; Piperacillin | 2019 |